Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Why is there an Adderall shortage? And what does it mean for patients?

By Brian Buntz | January 6, 2023

Adderall

[Image courtesy of Wikimedia Commons]

A widespread shortage of Adderall (amphetamine and dextroamphetamine) in the latter part of 2022 left millions of patients looking for an alternative treatment strategy or dealing with withdrawal symptoms.

A Sermo survey found that about half of 348 physicians had encountered patients dealing with the Adderall shortfall.

Of the physicians surveyed, 82%, were concerned about the impact of the shortage on adult patients’ quality of life, jobs and relationships. And 87% of physicians were worried about the effects of the shortage on children with ADHD and their parents.

Reasons for the Adderall shortage

Making sense of the situation remains challenging. The Drug Enforcement Administration (DEA) limits the production of Adderall and its generics. The federal agency is concerned that aggressive marketing practices contributed to the shortage, according to WSJ.

Teva (NYSE:TEVA) partly blamed labor shortages for low stockpiles of the drug. Novartis subsidiary Sandoz has also acknowledged manufacturing shortages related to generic Adderall.

The criteria for diagnosing ADHD have matured over the years. In 1968, the DSM-II included an entry for “hyperkinetic reaction of childhood,” a disorder involving “overactivity, restlessness, distractibility, and short attention span.” In 1980, the DSM-III had an entry for Attention-Deficit Disorder (ADD), which may include hyperactivity. Finally, the DSM-V, published in 2013, reframed the disorder as Attention-Deficit/Hyperactivity Disorder (ADHD).

Although the diagnostic criteria have grown more sophisticated, there’s still a lack of data about the long-term use of drug therapy for managing ADHD. However, a 2019 study published in the Journal of the American Academy of Child and Adolescent Psychiatry notes that currently available data “support continued effectiveness” of long-term drug therapy.

DEA signaled in December 2022 that it believes proposed Aggregate Production Quotas (APQs) for amphetamine are “sufficient to supply legitimate medical needs, reserve stocks, and export requirements for 2023.”

The impact of the pandemic on ADHD diagnoses

Dr. Heidi Moawad

Dr. Heidi Moawad

The pandemic also exacerbated ADHD symptoms for some patients, said Dr. Heidi Moawad, a neurologist on Sermo’s medical advisory board. The lockdown phase of the pandemic was trying for many people and likely amplified many ADHD symptoms.

“Think of all of the people who were inside and bored. Sports for kids weren’t as active as they normally are,” Moawad said. Additionally, many children could not go to school, leaving them with fewer outlets to blow off steam.

“Experts seem to agree that ADHD symptoms can change depending on the environment,” Moawad said. “And staying home during the pandemic was pretty bad for all of us.”

The pandemic also served as an opportunity to deal with symptoms that had been “on the back burner,” Moawad said. It may be that accounts of growing ADHD diagnoses involve people who were avoiding or too busy to go to the doctor before, she said.

Another factor contributing to the Adderall shortage is the growing popularity of telehealth paired with loosened restrictions on remotely prescribing controlled substances such as Adderall.

Last year, federal officials began investigating online mental health services startups Cerebral and Done Global over potential violations of the Controlled Substances Act. Both companies offered ADHD drugs such as Adderall via telehealth.

“Telehealth became so big during the pandemic,” Moawad said.

During the pandemic, many physicians realized how straightforward it could be to prescribe medications to patients where there are clear diagnostic criteria.

“But the biggest shortcoming of telehealth is you can’t do a good physical exam,” she said.

Telehealth, thus, can make physicians more reliant on questionnaires than an in-person visit would. Telehealth visits, however, can be more convenient for patients.

“Some people may try to just continue to get pharmaceutical prescriptions through telehealth because it was so easy [early on during the pandemic], and they don’t waste their time,” Moawad said.

Lobbyist Bart Stupak has asked the federal government to continue allowing physicians to keep prescribing controlled substances via telehealth, according to Bloomberg. Under the Ryan Haight Act passed in 2008, prescribing controlled substances requires a patient to visit a doctor in person. The DEA, however, relaxed that requirement in the early days of the pandemic.

How patients are dealing with the Adderall shortage

It is difficult for patients with ADHD to abruptly stop drug therapy without an alternate treatment in place. Adderall shortages could also impact behavioral modification efforts to treat ADHD.

“A lot of people with ADHD also will go to therapy and counseling,” said Moawad. “It’s believed to be effective if that’s happening at the same time as medical treatment.”

But an ADHD patient prescribed Adderall who suddenly doesn’t have access to the drug could suffer withdrawal symptoms, including depression, insomnia, fatigue and nausea. Those symptoms could interfere with behavioral modification.

In addition, while it has been established that behavioral modification and drug therapy work well in tandem, how well the former will work on its own is less clear.

“Are you putting too much of the burden on therapy?” asked Moawad.

The Adderall shortage can also prevent children from obtaining a medication that helps them effectively manage ADHD symptoms. Untreated ADHD can affect a child’s learning and social interactions, Moawad said.

The shortage could likely cause some children with ADHD to label themselves bad at academics or socializing, Dr. Moawad said.

“To not get treated would reaffirm that child’s belief that they’re not good at these things. And then it can make it a self-fulfilling prophecy,” she said, adding that such beliefs can have a long-lasting impact once entrenched.

The dangers of non-prescription stimulants and black market Adderall

In the Sermo survey, 74% of the physicians who took part in the survey feared that patients would look for alternative treatments to established medications such as Adderall. One option includes non-prescription stimulants, which are ill-suited for managing ADHD symptoms.

While some patients may look for prescription alternatives to the medication, counterfeit Adderall poses an array of dangers. The black-market product may be legitimate Adderall that is expired, while counterfeit Adderall may contain high levels of fentanyl, as Bloomberg noted.

“Patients might not take [the medication] according to instructions if they don’t have clear instructions from a pharmacist,” Moawad said. “And then if something is wrong, they can’t take it to their pharmacist and ask if it is OK.”

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Comments

  1. QT says

    January 30, 2023 at 10:13 pm

    Why is there an Adderall shortage? And what does it mean for patients?

    Sort of veered off the scope of the headline, don’t you think? I was hoping for some insight to the resolution of this huge problem, but instead got a lesson on ADHD. I’m an adult with Attention Deficit Disorder and this is a Gigantic problem for me. Finding out the DEA has a hand in this shortage does not surprise me. What I, as a reader would find helpful would be regularly updated information about the resolution, when the shortage is going to end, etc. Perhaps some investigation is due, call the DEA, call the FDA, call the manufacturers . Gather the information that is needed, and then provide it to your readers.

    The article itself was well put together and a good read, It’s just not what I was actually seeking. However, an e-mail would be appreciated if you happen to do an Informative follow up . Thank you so much Brian B.

    Regards,
    Q.T. (M 58)
    Clearwater FL

    Reply
  2. Dave says

    January 31, 2023 at 8:13 pm

    I am an adult with ADHD and recently started experiencing the shortage of this medication. 2 months ago my Dr. changed my prescription from XR to IR because my pharmacy did not have the XR. My pharmacy was having no issues with the IR version until this month. When I found out my regular pharmacy was out I had to call every one of the companies pharmacies within a 50 mile radius of me, all of them were out. I found a different pharmacy with a different supplier that had 150 of my medication in stock. By the time my prescription was transferred to this new pharmacy they were out of stock. I found out there is a pharmacy 65 miles away that has my medication in stock and I began the process of transferring me prescription to them. Will they have it in stock when my prescription gets transferred? Only time will tell and time is not on my side. We need an explanation and an ETA of when this shortage will be over.

    Reply
  3. Allen Bailey says

    March 9, 2023 at 9:21 pm

    I have narcolerpsy and ADHD. This govermental meddling is detrimental to my education and ability to work. I am trying to retrain to enhance my work to make more money and find a job that I like. This “shortage” is sabotaging my efforts.

    Reply
  4. Over It says

    June 24, 2023 at 7:56 am

    No one mentions the zip code restrictions for filling ADHD meds either. As of January 2023 in Nevada, I have to fill my meds at a pharmacy in my zip code. No other pharmacy outside my zip code will fill my ADHD meds. All 5 pharmacies in my area are out of Adderall, and Vyvanse is insanely expensive without insurance, so I’m screwed.

    I’ve been on the same dose of Adderall for 16 years, and usually pay cash. I make $17/hour, so too much to qualify for govt healthcare, but not enough to pay $160 a month for employer health insurance, plus the $20 co-pay for meds every month, and the $75 doctor appt every 3 months.

    I know being a “cash” patient puts me in some “drug abuse potential bracket” but with a discount card, I was paying around $50/month for generic Adderall without insurance. I’m sorry I can’t afford health insurance. I’m sorry I’m not useful without drugs to hold my attention. I’m sorry I was born, which is why I’m never having kids. That’s the one thing I’ve done right in my life.

    Anyways, good luck.

    Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE